53 related articles for article (PubMed ID: 31540779)
1. Availability of Naloxone in Pharmacies and Knowledge of Pharmacy Staff Regarding Dispensing Naloxone to Younger Adolescents.
Jimenez DE; Singer MR; Adesman A
J Adolesc Health; 2019 Nov; 65(5):698-701. PubMed ID: 31540779
[TBL] [Abstract][Full Text] [Related]
2. Naloxone Accessibility by Standing Order in North Carolina Community Pharmacies.
Marley G; Annis IE; Ostrach B; Egan K; Delamater PL; Bell R; Dasgupta N; Carpenter DM
J Am Pharm Assoc (2003); 2024; 64(3):102021. PubMed ID: 38307248
[TBL] [Abstract][Full Text] [Related]
3. Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies.
Freeman PR; Hammerslag LR; Ahrens KA; Sharbaugh M; Gordon AJ; Austin AE; Donohue JM; Allen LD; Barnes AJ; Talbert JC
JAMA Health Forum; 2024 May; 5(5):e241077. PubMed ID: 38758569
[TBL] [Abstract][Full Text] [Related]
4. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
[TBL] [Abstract][Full Text] [Related]
5. Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire.
Bolivar D; Hartung D; Silcox J; Bratberg J; Boggis J; Rabin M; Green TC
J Am Pharm Assoc (2003); 2023; 63(1):330-335.e1. PubMed ID: 36369076
[TBL] [Abstract][Full Text] [Related]
6. Naloxone availability in independent community pharmacies in Georgia, 2019.
Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
[TBL] [Abstract][Full Text] [Related]
7. Naloxone Accessibility Under the State Standing Order Across Mississippi.
Gravlee E; Ramachandran S; Cafer A; Holmes E; McGregor J; Jordan T; Rosenthal M
JAMA Netw Open; 2023 Jul; 6(7):e2321939. PubMed ID: 37410464
[TBL] [Abstract][Full Text] [Related]
8. Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas.
Evoy KE; Hill LG; Groff L; Mazin L; Carlson CC; Reveles KR
JAMA; 2018 Nov; 320(18):1934-1937. PubMed ID: 30422186
[TBL] [Abstract][Full Text] [Related]
9. ASAP: A pharmacy-level intervention to increase nonprescription syringe sales to reduce bloodborne illnesses.
Meyerson BE; Agley J; Crosby RA; Bentele KG; Vadiei N; Linde-Krieger LB; Russell DR; Fine K; Eldridge LA
Res Social Adm Pharm; 2024 Aug; 20(8):778-785. PubMed ID: 38734511
[TBL] [Abstract][Full Text] [Related]
10. Socio-ecological and pharmacy-level factors associated with naloxone stocking at standing-order naloxone pharmacies in New York City.
Abbas B; Marotta PL; Goddard-Eckrich D; Huang D; Schnaidt J; El-Bassel N; Gilbert L
Drug Alcohol Depend; 2021 Jan; 218():108388. PubMed ID: 33285392
[TBL] [Abstract][Full Text] [Related]
11. Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia.
Karthikeyan N; Xia T; Nielsen S; Picco L
Drug Alcohol Rev; 2024 May; ():. PubMed ID: 38691509
[TBL] [Abstract][Full Text] [Related]
12. The association between naloxone claims and proportion of independent vs. chain pharmacies: A longitudinal analysis of naloxone claims in the US.
Freibott CE; Jalali A; Murphy SM; Walley AY; Linas BP; Jeng PJ; Bratberg J; Marshall BDL; Zang X; Green TC; Morgan JR
J Am Pharm Assoc (2003); 2024 Apr; ():102093. PubMed ID: 38604474
[TBL] [Abstract][Full Text] [Related]
13. Implementation Documentation and Process Assessment of the PharmNet Intervention: Observational Report.
Eldridge LA; Meyerson BE; Agley J
JMIR Form Res; 2024 Mar; 8():e54077. PubMed ID: 38498037
[TBL] [Abstract][Full Text] [Related]
14. Availability of naloxone in Canadian pharmacies:a population-based survey.
Cressman AM; Mazereeuw G; Guan Q; Jia W; Gomes T; Juurlink DN
CMAJ Open; 2017 Nov; 5(4):E779-E784. PubMed ID: 29117991
[TBL] [Abstract][Full Text] [Related]
15. Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City.
Marotta PL; Abbas BT; Stringer K; Huang D; Schnaidt J; Goddard-Eckrich D; El-Bassel N; Gilbert L
Int J Drug Policy; 2021 Nov; 97():103321. PubMed ID: 34358803
[TBL] [Abstract][Full Text] [Related]
16. Topical Corticosteroid Phobia among Danish Pharmacy Staff.
Toft-Hansen JM; Nørreslet LB; Vittrup I; Thyssen JP; Agner T; Yüksel YT
Dermatology; 2024 Apr; ():1-8. PubMed ID: 38679004
[TBL] [Abstract][Full Text] [Related]
17. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Naloxone by Payer Type.
Jiang X; Strahan AE; Zhang K; Guy GP
JAMA; 2024 Feb; 331(8):700-702. PubMed ID: 38285437
[TBL] [Abstract][Full Text] [Related]
18. Trends in Naloxone Dispensing From Retail Pharmacies in the US.
Rikard SM; Strahan AE; Schieber LZ; Guy GP
JAMA; 2024 Jun; ():. PubMed ID: 38869869
[TBL] [Abstract][Full Text] [Related]
19. The status of naloxone in community pharmacies across Canada.
So R; Al Hamarneh Y; Barnes M; Beazely MA; Boivin M; Laroche J; Patel H; Sihota A; Smith T; Tsuyuki RT
Can Pharm J (Ott); 2020; 153(6):352-356. PubMed ID: 33282025
[No Abstract] [Full Text] [Related]
20. Acute opioid overdose in pediatric patients.
Sandelich S; Hooley G; Hsu G; Rose E; Ruttan T; Schwarz ES; Simon E; Sulton C; Wall J; Dietrich AM
J Am Coll Emerg Physicians Open; 2024 Apr; 5(2):e13134. PubMed ID: 38464332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
